Select a medication above to begin.
Atzumi
dihydroergotamine nasal
Black Box Warnings .
content coming soon
Adult Dosing .
Dosage forms: PWDR: 5.2 mg per device
New FDA Approval: April 2025
- [content coming soon]
migraine, acute
- [content coming soon]
- Info: activates vascular serotonin 5-HT1D receptors, constricting cranial and peripheral blood vessels (ergot alkaloid)
Peds Dosing .
- Dosage forms: --
New FDA Approval: April 2025
- [Peds dosing is not applicable for this drug]